@article{9fa33f5d76f84d84b1e6a4058437330c,
title = "Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder",
abstract = "Antidepressants have reduced the symptom burden for many Major Depressive Disorder (MDD) patients, but drug-related side effects and treatment resistance continue to present major challenges. Pharmacogenomics represents one approach to enhance antidepressant efficacy and avoid adverse reactions, but concerns remain with regard to the overall “value equation,” and several barriers must be overcome to achieve the full potential of MDD pharmacogenomics.",
author = "Ahmed, {Ahmed T.} and Richard Weinshilboum and Frye, {Mark A.}",
note = "Funding Information: Dr. Ahmed is supported by the Mayo Clinic NIH Clinical Pharmacology Training Grant T32 GM008685. Funding Information: Dr. Frye has received grant support from AssureRx Health Inc., Myriad, Pfizer Inc., NIMH (R01 MH079261), the National Institute on Alcohol Abuse and Alcoholism (P20AA017830) in the National Institutes of Funding Information: Health at the US Department of Health and Human Services, and the Mayo Foundation. He has been a consultant (for Mayo) to Janssen Global Services, LLC; Mitsubishi Tanabe Pharma Corp.; Myriad Genetics, Inc.; Sunovion Pharmaceuticals, Inc.; and Teva Pharmaceutical Industries Ltd. He has received continuing medical education, travel, and presentation support from American Physician Institute and CME Outfitters. Dr. Wein-shilboum is supported by NIH grants RO1 GM28157, U19 GM61388, U54 GM114838, and NSF1624615. Dr. Weinshilboum is a cofounder and stockholder in OneOme. The Mayo Clinic has a financial interest in OneOme. Funding Information: Dr. Ahmed is supported by the Mayo Clinic NIH Clinical Pharmacology Training Grant T32 GM008685. Dr. Frye has received grant support from AssureRx Health Inc., Myriad, Pfizer Inc., NIMH (R01 MH079261), the National Institute on Alcohol Abuse and Alcoholism (P20AA017830) in the National Institutes of Health at the US Department of Health and Human Services, and the Mayo Foundation. He has been a consultant (for Mayo) to Janssen Global Services, LLC; Mitsubishi Tanabe Pharma Corp.; Myriad Genetics, Inc.; Sunovion Pharmaceuticals, Inc.; and Teva Pharmaceutical Industries Ltd. He has received continuing medical education, travel, and presentation support from American Physician Institute and CME Outfitters. Dr. Weinshilboum is supported by NIH grants RO1 GM28157, U19 GM61388, U54 GM114838, and NSF1624615. Dr. Weinshilboum is a cofounder and stockholder in OneOme. The Mayo Clinic has a financial interest in OneOme. Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Pharmacology and Therapeutics",
year = "2018",
month = may,
doi = "10.1002/cpt.1009",
language = "English (US)",
volume = "103",
pages = "767--769",
journal = "Clinical pharmacology and therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",
}